Literature DB >> 24641390

Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.

Neda Moazzezy1, Tahereh Zarnoosheh Farahany, Mana Oloomi, Saeid Bouzari.   

Abstract

BACKGROUND: CEA and CA 15.3 serum tumor markers are currently used in clinical practice for monitoring therapy. The aim of this study was to evaluate serum level of these markers among healthy females and invasive breast carcinoma (IBC) patients and to determine any relationships with clinicopathological factors.
MATERIALS AND METHODS: 60 Iranian females were enrolled in this study, 30 healthy and 30 diagnosed with breast cancer who had not received any preoperative chemotherapy or hormone therapy. Enzyme linked immunosorbent assays were used for the quantitative determination of the cancer associated antigens, CEA and MUC1 (CA 15- 3).
RESULTS: The serological levels of CEA and CA 15-3 (5.0033 ± 0.49 μg/L and 178.1667 ± 15.11 U/ml) in the breast cancer patients were significantly higher (p=0.00) than the serum levels of normal controls (1.1237 ± 0.11 μg/L and 21.13 ± 3.058 U/ml). Regarding the CEA marker, a significant correlation with grade of tumor was shown. Furthermore, there was a low correlation between CA 15-3 and CEA marker with correlation coefficient r=0.08.
CONCLUSIONS: Collectively, markedly high levels of CEA and CA 15-3 were found in our patients, pointing to their use as additional tools after clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641390     DOI: 10.7314/apjcp.2014.15.4.1685

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  11 in total

1.  Analysis of blood markers for early breast cancer diagnosis.

Authors:  J Bayo; M A Castaño; F Rivera; F Navarro
Journal:  Clin Transl Oncol       Date:  2017-08-14       Impact factor: 3.405

2.  CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors.

Authors:  Mohit Jain; Shailesh D Ingole; Rahul S Deshmukh; Simin V Bharucha; Anagha S Nagvekar; Rajiv V Gaikwad; Shambhudeo D Kharde
Journal:  Chromosome Res       Date:  2021-02-27       Impact factor: 5.239

3.  Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis.

Authors:  Yijie Fu; Hui Li
Journal:  Med Sci Monit       Date:  2016-09-06

Review 4.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

5.  Comparison of breast cancer risk factors among molecular subtypes: A case-only study.

Authors:  Liwen Zhang; Yubei Huang; Ziwei Feng; Xin Wang; Haixin Li; Fangfang Song; Luyang Liu; Junxian Li; Hong Zheng; Peishan Wang; Fengju Song; Kexin Chen
Journal:  Cancer Med       Date:  2019-02-14       Impact factor: 4.452

Review 6.  Genetic and molecular biology of breast cancer among Iranian patients.

Authors:  Meysam Moghbeli
Journal:  J Transl Med       Date:  2019-07-08       Impact factor: 5.531

7.  Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma.

Authors:  Mana Oloomi; Neda Moazzezy; Saeid Bouzari
Journal:  Biomed Res Int       Date:  2018-02-12       Impact factor: 3.411

8.  Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.

Authors:  Cheng Fang; Yue Cao; Xiaoping Liu; Xian-Tao Zeng; Yirong Li
Journal:  Oncotarget       Date:  2017-07-12

Review 9.  Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.

Authors:  Wenyong Tan; Ming Yang; Hongli Yang; Fangbin Zhou; Weixi Shen
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

10.  Comparative Study of Blood, Tissue and Serum Levels of Carcinoembryonic Antigen (CEA) Detection in Breast Cancer.

Authors:  Neda Moazzezy; Saeid Bouzari; Mana Oloomi
Journal:  Asian Pac J Cancer Prev       Date:  2019-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.